in #CASE you missed it… Blood pressure medication recall expands. Possible cancer risk
A widespread recall of common blood pressure and heart failure medications has been expanded to include more drugs containing losartan making the total for one week to four recalls.
The recall is due to an "impurity" that is classified as a potential human carcinogen.
The impurity, N-Nitroso-N-methyl-4-aminobutyric acid or NMBA, is also classified as a known animal carcinogen, the U.S. Food and Drug Administration noted in a news release about the recall Friday.
Camber Pharmaceuticals Inc. voluntarily recalled 87 lots of losartan tablets in the United States Thursday. The recalled tablets, made by Hetero Labs Ltd. in India and distributed by Camber Pharmaceuticals, were found to contain trace amounts of the impurity.
The recall noted that Camber has not received any reports of adverse events related to the recall.
The recall is the latest in an ongoing investigation into a class of drugs known as angiotensin receptor blockers or ARBs, which contain either valsartan, losartan or irbesartan and are used in patients with high blood pressure and other conditions.